No headlines found.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 12-Apr 4:15 PM ET)
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
Business Wire (Tue, 19-Mar 7:00 AM ET)
Scholar Rock to Participate in Upcoming Investor Conferences
Business Wire (Wed, 28-Feb 8:00 AM ET)
Business Wire (Thu, 15-Feb 8:00 AM ET)
Business Wire (Tue, 6-Feb 8:00 AM ET)
Business Wire (Thu, 25-Jan 8:00 AM ET)
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFß1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Scholar Rock Holding trades on the NASDAQ stock market under the symbol SRRK.
As of April 25, 2024, SRRK stock price declined to $14.00 with 166,654 million shares trading.
SRRK has a beta of 0.77, meaning it tends to be less sensitive to market movements. SRRK has a correlation of 0.01 to the broad based SPY ETF.
SRRK has a market cap of $1.09 billion. This is considered a Small Cap stock.
In the last 3 years, SRRK stock traded as high as $44.95 and as low as $4.33.
The top ETF exchange traded funds that SRRK belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWN.
SRRK has outperformed the market in the last year with a price return of +90.7% while the SPY ETF gained +22.7%. However, in the short term, SRRK had mixed performance relative to the market. It has underperformed in the last 3 months, returning -5.0% vs +3.2% return in SPY. But in the last 2 weeks, SRRK shares have fared better than the market returning -0.1% compared to SPY -2.8%.
SRRK support price is $13.40 and resistance is $14.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRRK stock will trade within this expected range on the day.